The Effect of Upper Limb Low-intensity Motor Control Training Program on Cognitive Function in Healthy Older Adults
uMCON
1 other identifier
interventional
24
1 country
1
Brief Summary
This healthy volunteer intervention study is designed to evaluate the effectiveness of upper limb motor control training (uMCT) on physical and cognitive functions in older adults. The primary objectives of the study are twofold: Assess the Impact on Physical and Neuromuscular Function: The study seeks to determine whether uMCT positively influences physical performance, including motor coordination and neuromuscular function, in older adults. Assessment the Impact on Cognitive Function: The study aims to investigate whether uMCT enhances cognitive abilities in older adults. In addition to these main goals, the study will also assess the feasibility and safety of implementing uMCT in an older adult population. The main questions it aims to answer are: Does uMCON training have a positive effect on physical function and neuromuscular function in older adults? Does uMCON training have a positive effect on cognitive function in older adults? The researchers designed this study to show whether uMCON training works on physical function (balance, gait, and so on) and cognition in older adults. Participants will come to Derby Royal Hospital Medical School to attend uMCON training three days a week for 1 month. They will attend pre-training, post-training, and follow-up (after 1 month) control assessment sessions.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Sep 2023
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2023
CompletedFirst Submitted
Initial submission to the registry
September 27, 2024
CompletedFirst Posted
Study publicly available on registry
May 8, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 31, 2026
May 8, 2025
April 1, 2025
2.7 years
September 27, 2024
April 29, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Outcome Measure Title: Rate of participants whose cognition improved with upper limb motor control training.
Number of Participants: 20 Control group: No Rate of Female/Male: 50%/ 50% Time frame: 1 month upper limb neuromuscular training Assessment time: Pre-training, Post-training, Follow-up(after 4 weeks) Cognition questionnaire is used (MOCA).
Baseline, 4 week, and 8 week
Secondary Outcomes (2)
Clinically relevant functional outcomes (motor control, strength, dexterity, overall physical function)
Baseline, 4 week, and 8 week
Plasma pro/anti-inflammatory cytokine levels
Baseline, 4 week, and 8 week
Study Arms (1)
Intervention Group
EXPERIMENTALuMCON training group
Interventions
The exercise program protocol was determined using elbow flexion (Biceps brachii) and elbow extension (Triceps) on a special platform developed for the arm. In this computer-based exercise, participants are asked to follow a small ball on the screen in different lines at certain percentages of maximum muscle strength (10%, 25%, 50%, and so on). Neuromuscular training will be worked on with this exercise.
Eligibility Criteria
You may qualify if:
- Willing and able to give informed consent for participation in the study
- Aged between 65-85 years
You may not qualify if:
- Diagnosis of cognitive impairment
- Current or recent (\<5y) malignancy
- History of or current psychiatric illness
- History of or current neurological condition (e.g., epilepsy, Parkinsons disease, cerebrovascular disease)
- Severe respiratory disease (e.g., uncontrolled asthma, COPD, pulmonary hypertension)
- Active cardiovascular disease: Uncontrolled hypertension (BP\>160/100mmHg); Recent (\<12mo) cardiac event; Heart failure (Class III/IV); Significant arrhythmia; Unstable angina
- Metabolic disease: Untreated hyper/hypo-parathyroidism; Cushing's disease; Type 1 or 2 diabetes
- Significant musculoskeletal disorders (based on clinical opinion)
- Family history of early (\<55y) death from cardiovascular disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The University of Nottingham Medical School
Derby, Derbyshire, DE22 3DT, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Hatice Sirin Ekici, PhD
The University of Nottingham
- STUDY DIRECTOR
Mehmet C Yildirim, PhD
The University of Nottingham
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
September 27, 2024
First Posted
May 8, 2025
Study Start
September 1, 2023
Primary Completion (Estimated)
May 31, 2026
Study Completion (Estimated)
May 31, 2026
Last Updated
May 8, 2025
Record last verified: 2025-04
Data Sharing
- IPD Sharing
- Will not share
Access to personal (identifiable) information is limited only to research staff involved in the participation elements of this study, and to audit staff as detailed above.